ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

Prof. François-Clément Bidard and Dr Barbara Pistilli share expert insights on the latest TROPION-Breast01 update, presenting the final OS results from the ESMO Virtual Plenary 2025.

This study evaluates datopotamab deruxtecan (Dato-DXd) versus chemotherapy in previously treated, inoperable or metastatic HR+/HER2– breast cancer. 

In this video, the experts explore: 

• Mechanism of action of Dato-DXd 
• TROPION-Breast01 PFS results and safety outcomes 
• Final overall survival results and their clinical implications 
• The future outlook for Dato-DXd 

Clinical takeaways

• TROPION-Breast01 final OS results did not reach statistical significance; however, subsequent ADC treatment may have influenced survival outcomes
• The dual primary endpoint of PFS demonstrates a statistically significant and clinically meaningful improvement with Dato-DXd compared with chemotherapy
• Secondary efficacy and PRO endpoints continued to show a benefit for Dato-DXd in this final analysis

Download the Virtual Plenary slides from ESMO's OncologyPro website: www.oncologypro.esmo.org